NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

CompletedN/A

Sponsor: AstraZeneca

Conditions: Advanced Ovarian Cancer

Interventions: None (Observational Study)

Countries: United States

This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.

Eligibility overview

Sex: FEMALE

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Female adult, age ≥ 18 years
* BRCAwt AOC diagnosed with any approved BRCA test
* Has documented HRD status based on available test results
* Received 1L olaparib maintenance monotherapy following platinum chemotherapy
* Patients must have been treated with platinum-based chemotherapy at first-line

Exclusion Criteria:

* Received another poly adenosine diphosphate ribose polymerase (PARP) inhibitor or bevacizumab before or while prescribed olaparib
* Participation in an interventional clinical study

Locations (7)

Tampa, Florida, United States
Shreveport, Louisiana, United States
Annapolis, Maryland, United States
Baltimore, Maryland, United States
New York, New York, United States
Charlotte, North Carolina, United States
Madison, Wisconsin, United States